Mycophenolate sodium controlled release - Novartis

Drug Profile

Mycophenolate sodium controlled release - Novartis

Alternative Names: EC-MPS; ERL 080; ERL 080A; Mycophenolic acid - Novartis; Myfortic

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; University of Pittsburgh
  • Class Benzofurans; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lupus nephritis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase II Liver transplant rejection
  • No development reported Heart transplant rejection; Lupus nephritis

Most Recent Events

  • 27 Jan 2017 Novartis has patent protection for mycophenolate sodium in USA and Europe (Novartis 20-F filed in 2017)
  • 09 Jan 2014 First generic equivalent available in USA for Renal transplant rejection
  • 18 Nov 2009 Novartis completes a phase II trial in Lupus nephritis in Hungary, France, Great Britain, Greece, Denmark, Italy and Spain (EudraCT2006-002107-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top